InflaRx Announces Encouraging Phase III Topline Results From PANAMO Trial Of Vilobelimab In Severe COVID-19 Patients [TheStreet.com]
InflaRx N.V. (IFRX)
Last inflarx n.v. earnings: 8/14 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
Company Research
Source: TheStreet.com
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpoint Pre-specified sensitivity analysis of the primary endpoint results in p-values of 43% relative reduction in 28-day all-cause mortality detected in pre-specified subgroup analysis in Western European patients comparing vilobelimab to placebo treatment (n=209, p-value=0.014) Additional pre-specified subgroup analyses in patients with more severe disease confirm treatment benefit for vilobelimab, resulting in p-values of Company plans to discuss results with regulatory authorities Company to host a conference call today at 8:30 am EDT/2:30 pm CEST JENA, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that the Phase I
Show less
Read more
Impact Snapshot
Event Time:
IFRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IFRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IFRX alerts
High impacting InflaRx N.V. news events
Weekly update
A roundup of the hottest topics
IFRX
News
- InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024GlobeNewswire
IFRX
Earnings
- 5/8/24 - Beat
IFRX
Sec Filings
- 5/8/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/4/24 - Form 6-K
- IFRX's page on the SEC website